Zymeworks adds lung disease drug, royalty deals in nearly $1B pick up of Theravance
BioSpace covers Zymeworks' near-$1B acquisition of Theravance, which brings a lung-disease drug candidate plus royalty streams into the acquirer's portfolio.
Zymeworks
Zymeworks is a clinical-stage biotechnology company developing multifunctional biotherapeutics for difficult-to-treat cancers. The company's platforms include Azymetric (bispecific antibodies) and EFECT (immune-effector modulation), and it is advancing multiple wholly-owned and partnered oncology candidates. In 2026 Zymeworks expanded its pipeline through the near-$1B acquisition of Theravance Biopharma, adding a lung-disease drug candidate plus royalty streams.
Company Info
Sector:Biotechnology / Oncology Biotherapeutics
Headquarters:Vancouver, British Columbia, Canada
Founded:2003
Website:www.zymeworks.com/
Upcoming Milestones & Key Dates
Q3 2026
Corporate
Theravance Biopharma acquisition close (~$1B deal announced June 2026)
H2 2026
Clinical Trial
Zanidatamab regulatory and clinical readouts in BTC and GEA
Clinical Development Pipeline
Zanidatamab (ZW25)
Target: Bispecific antibody targeting two HER2 epitopesZanidatamab + chemo / ZW49
Target: HER2 bispecific + topoisomerase-based ADCTheravance-originated lung-disease candidate
Target: To be confirmedRecent News
Zymeworks to acquire troubled biotech Theravance in $929M deal
Endpoints News reports on Zymeworks' $929M acquisition of Theravance Biopharma, adding a lung-disease drug candidate and royalty streams to the acquirer's pipeline.
Leadership Team
Kenneth Galbraith
Chair of the Board (interim CEO transition period)
Dr. Sabeen Mekan
Chief Medical Officer
Mark Hollywood
Chief Operating Officer
Careers & Job Openings